These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 36142518)

  • 1. The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches.
    Lugnier C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in phosphodiesterase activity in the developing rat submandibular gland.
    Tanaka S; Shimooka S; Shimomura H
    Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
    Suvarna NU; O'Donnell JM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.
    Zhao CY; Greenstein JL; Winslow RL
    J Mol Cell Cardiol; 2015 Nov; 88():29-38. PubMed ID: 26388264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K; Kass DA
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
    Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
    Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.
    Keravis T; Lugnier C
    Br J Pharmacol; 2012 Mar; 165(5):1288-305. PubMed ID: 22014080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
    Erdogan S; Houslay MD
    Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: differential regulation in cobblestone and spindle phenotypes.
    Keravis T; Komas N; Lugnier C
    J Vasc Res; 2000; 37(4):235-49. PubMed ID: 10965223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
    Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
    Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
    Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
    Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system.
    Maurice DH
    Front Biosci; 2005 May; 10():1221-8. PubMed ID: 15769620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic nucleotide phosphodiesterases in Drosophila melanogaster.
    Day JP; Dow JA; Houslay MD; Davies SA
    Biochem J; 2005 May; 388(Pt 1):333-42. PubMed ID: 15673286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of cyclic AMP phosphodiesterases and adenylyl cyclase in peripheral nerve after crush and permanent transection injuries.
    Walikonis RS; Poduslo JF
    J Biol Chem; 1998 Apr; 273(15):9070-7. PubMed ID: 9535895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells.
    Zhang L; Bouadjel K; Manoury B; Vandecasteele G; Fischmeister R; Leblais V
    Br J Pharmacol; 2019 Jun; 176(11):1780-1792. PubMed ID: 30825186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
    Lugnier C
    Pharmacol Ther; 2006 Mar; 109(3):366-98. PubMed ID: 16102838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.